Format

Send to

Choose Destination
Alzheimers Dement. 2014 May;10(3):409-15. doi: 10.1016/j.jalz.2013.03.006. Epub 2013 Sep 10.

Design of a comprehensive Alzheimer's disease clinic and research center in Spain to meet critical patient and family needs.

Author information

1
Alzheimer Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain. Electronic address: mboada@Fundacioace.com.
2
Alzheimer Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
3
Alzheimer Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain; Servei de Psiquiatria, Hospital Universitari Vall d'Hebron, CIBERSAM, Universitat Autònoma de Barcelona, Barcelona, Spain.
4
Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, PA, USA.

Abstract

OBJECTIVES:

Alzheimer's disease (AD) affects people worldwide, and the prevalence is increasing as the population ages. There is an international effort to understand the biology of AD to develop primary and secondary prevention strategies, and to develop effective therapeutic interventions for individuals who are already symptomatic. One of the critically important pieces of all national plans to address AD is the call for the development of service models to deliver quality, effective care based on the best evidence available.

METHODS:

We describe one type of care model developed by the Fundacio ACE, Institut Catala de Neurociencies Aplicades (Fundacio ACE, Barcelona, Spain) that integrates diagnosis, therapy, follow-up care, daycare, and a day hospital, and does so in the context of an active clinical research and educational program.

RESULTS:

There were 13,048 individuals newly evaluated and diagnosed in Fundacio ACE between 1996 and 2011. Of these, 6132 had AD (47.0%), 3871 had mild cognitive impairment (MCI) (29.7%), and 1958 had no cognitive impairment (15.0%). Follow-up information is available on 4735 (47.3%) AD and MCI patients, and these data indicate that MCI develops into dementia at a rate of 222.6/1000 person-years. Apolipoprotein E (APOE) genotyping was available in 22.4% of the patients. The ε4 allele occurred in 45.7% of the AD patients, in 37.8% of the MCI subjects, and in 31.6% of those without cognitive impairment.

CONCLUSIONS:

Fundació ACE can serve as a model system that can be adapted to other settings within their specific cultural, governmental, and legal constraints.

KEYWORDS:

Alzheimer’s disease; Dementia; Natural history; Spain

PMID:
24035148
PMCID:
PMC3951687
DOI:
10.1016/j.jalz.2013.03.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center